Capital Fund Management (CFM)
KYMR icon

Capital Fund Management (CFM)’s Kymera Therapeutics KYMR Stock Holding History

Capital Fund Management (CFM)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,440
Closed -$494K – 2156
2024
Q3 		$494K Sell
10,440
-19,512
-65% -$862K ﹤0.01% 1846
2024
Q2 		$894K Buy
+29,952
New +$1.04M ﹤0.01% 1641
2022
Q4 		– Sell
-11,520
Closed -$251K – 1515
2022
Q3 		$251K Buy
+11,520
New +$304K ﹤0.01% 1370

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Capital Fund Management (CFM)'s KYMR Position: Q4 2024 in Review

Capital Fund Management (CFM) sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 10,440 shares — an estimated $494K sold.

Capital Fund Management (CFM) first reported a position in KYMR in Q3 2022 and held it in 3 quarters. The position peaked at $894K in Q2 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • Capital Fund Management (CFM) reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 10,440 Kymera Therapeutics shares in Q4 2024, an estimated $494K.
  • Capital Fund Management (CFM) first reported a position in Kymera Therapeutics in Q3 2022 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Kymera Therapeutics position peaked at $894K in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2024, filed 13 Feb 2025.